BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 2021;75:454-61. [PMID: 34019941 DOI: 10.1016/j.jhep.2021.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu X, Nan Y. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease". J Hepatol 2021:S0168-8278(21)02170-X. [PMID: 34774637 DOI: 10.1016/j.jhep.2021.11.003] [Reference Citation Analysis]
2 Lee C. Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.01.005] [Reference Citation Analysis]
3 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
4 Zhou YJ, Zheng MH. Editorial: an elastography-based two-step approach to detect NAFLD with compensated advanced chronic liver disease-authors' reply. Aliment Pharmacol Ther 2021;54:517-8. [PMID: 34331809 DOI: 10.1111/apt.16528] [Reference Citation Analysis]
5 Wang X, Li X, Jin R, Yang J, Huang R, Wei L, Liu F, Rao H. Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study. Hepatol Commun 2022. [PMID: 35560825 DOI: 10.1002/hep4.1990] [Reference Citation Analysis]
6 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Shaltout I, Alkandari H, Fouad Y, Hamed AE. Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. J Hepatol 2021:S0168-8278(21)02236-4. [PMID: 34875311 DOI: 10.1016/j.jhep.2021.11.027] [Reference Citation Analysis]
8 Wang YZ. MAFLD supported by 95.45% participants of CSH is NOT representative. J Hepatol 2021:S0168-8278(21)00420-7. [PMID: 34153397 DOI: 10.1016/j.jhep.2021.06.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang X, Liu X, He P, Guan K, Yang Y, Lei Y, Cai J, Wang W, Wu T, Rauf A. The Imbalance of Mitochondrial Homeostasis of Peripheral Blood-Derived Macrophages Mediated by MAFLD May Impair the Walking Ability of Elderly Patients with Osteopenia. Oxidative Medicine and Cellular Longevity 2022;2022:1-21. [DOI: 10.1155/2022/5210870] [Reference Citation Analysis]
10 Sun Q, Tang L, Wang M, Zhu P, Li Y, Ma H, Huang O, Hong L, Li G, Byrne CD, Targher G, Liu W, Lu Y, Ding J, Zheng M. Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Front Med 2022;9:864570. [DOI: 10.3389/fmed.2022.864570] [Reference Citation Analysis]
11 El-Shabrawi M, Memon I, Attia D, El-Koofy NM. The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease. J Hepatol 2021:S0168-8278(21)02221-2. [PMID: 34813920 DOI: 10.1016/j.jhep.2021.11.016] [Reference Citation Analysis]
12 Fouad Y, Méndez-Sánchez N, Zheng MH. One Not Like the Other: The weakness of the blood sugar-MAFLD analogy. J Hepatol 2021:S0168-8278(21)02117-6. [PMID: 34678406 DOI: 10.1016/j.jhep.2021.10.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Méndez-Sánchez N, Maris-Gil S, Alonso-Rivera CG. Latin American Association of Pediatrics (ALAPE) endorsing the MAFLD definition of fatty liver disease. J Hepatol 2021:S0168-8278(21)02297-2. [PMID: 34968579 DOI: 10.1016/j.jhep.2021.12.020] [Reference Citation Analysis]
14 Xie X, Guo B, Xiao X, Yin J, Wang Z, Jiang X, Li J, Long L, Zhou J, Zhang N, Zhang Y, Chen T, Kangzhuo B, Zhao X. Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study. BMC Public Health 2022;22:118. [PMID: 35038997 DOI: 10.1186/s12889-021-12486-x] [Reference Citation Analysis]
15 Wong VW, Lazarus JV. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. J Hepatol 2021:S0168-8278(21)02015-8. [PMID: 34464658 DOI: 10.1016/j.jhep.2021.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lonardo A. Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease. Clinical and Translational Dis 2021;1. [DOI: 10.1002/ctd2.9] [Reference Citation Analysis]
17 Xie Z, Li H, Tan W, Yang L, Ma X, Li W, Wang Q, Shang C, Chen Y. Association of Cholecystectomy With Liver Fibrosis and Cirrhosis Among Adults in the USA: A Population-Based Propensity Score-Matched Study. Front Med 2021;8:787777. [DOI: 10.3389/fmed.2021.787777] [Reference Citation Analysis]
18 Zheng MH. Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:793-4. [PMID: 34966641 DOI: 10.14218/JCTH.2021.00439] [Reference Citation Analysis]
19 Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, Tan DJH, Lim WH, Chan KE, Teng M, Tan E, Tamaki N, Huang DQ, Siddiqui MS, Young DY, Noureddin M, Muthiah MD. Metabolic Associated Fatty Liver Disease (MAFLD) Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12,620,736 Individuals. Endocr Pract 2022:S1530-891X(22)00102-1. [PMID: 35364328 DOI: 10.1016/j.eprac.2022.03.016] [Reference Citation Analysis]